Background: Isocitrate dehydrogenases (IDH) catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R-2-hydroxyglutarate. Elevated levels of R-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors.
Immunogen: A synthetic peptide from the internal region of IDH1 which includes the mutation of R132P, human origin.
Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 50% glycerol
Species Reactivity: recognizes R132P mutant, but not wild-type IDH2 of vertebrates.
Storage Conditions: Store at -20°C. Avoid freeze / thaw cycles
Western blot:
Western blot analysis of recombinant IDH1 (R132P) and wildtype proteins. Purified His-tagged IDH1 (R132P) (lane 1) and corresponding wild-type IDH1 protein (lane 2) were blotted with anti-IDH1 (R132P) monoclonal antibody (Cat. #26406).
Immunofluorescence:
Immunofluorescence of cells expressing IDH1 proteins with anti-IDH1 (R132P) antibody. HEK293T cells were transfected with pCDNA3-GFP-IDH1(R132P) plasmid, pCDNA3-GFP-IDH1 (WT) plasmid , pCDNA3-GFP-IDH1(R132S) plasmid, pCDNA3-GFP-IDH1(R132L) plasmid , pCDNA3-GFP-IDH1(R132G) plasmid or pCDNA3-GFP-IDH1(R132C) plasmid , then fixed and stained with anti-IDH1 (R132P) monoclonal antibody (Cat. #26406).